“Pharmacokinetics and Safety of FIC CLDN18.2/4-1BB Bispecific Antibody PM1032 in Rhesus Monkeys”

https://pubmed.ncbi.nlm.nih.gov/38115178

The FIC CLDN18.2/4-1BB bispecific antibody, PM1032, demonstrated good pharmacokinetics and an exceptional safety profile in rhesus monkeys, supporting its potential as an effective treatment for CLDN18.2 positive cancers.